Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

NCT01368848 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Bevacizumab
DRUG: Cisplatin
DRUG: Docetaxel

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]
[object Object]